Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763691 | 0.82 | KDM4E (0.41) | KDM4EGLAMEN1KMT2AGAA | |
| SCHEMBL12216940 | 0.81 | ALDH1A1 (0.41) | MEN1KMT2ATP53GAAALDH1A1 | |
| SCHEMBL22343618 | 0.77 | KDM4E (0.38) | KDM4EGLAMEN1KMT2ARAB9A | |
| SCHEMBL12349177 | 0.75 | POLB (0.40) | KDM4EMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25135334 | 0.75 | DRD2 (0.37) | MEN1KMT2ATP53 | |
| SCHEMBL23706760 | 0.75 | DRD2 (0.37) | MEN1KMT2ATP53 | |
| SCHEMBL23706769 | 0.72 | DRD2 (0.38) | KDM4EALDH1A1LMNAUSP2ALOX15 | |
| SCHEMBL25135126 | 0.72 | DRD2 (0.38) | KDM4EALDH1A1LMNAUSP2ALOX15 | |
| SCHEMBL23171105 | 0.72 | LPAR1 (0.42) | ALDH1A1USP2HSD17B10 | |
| SCHEMBL20356865 | 0.72 | KDM4E (0.39) | KDM4EGLAMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-05-19 | — | — | US | disclosed |
| EP-3225621-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2017-10-04 | — | — | EP | disclosed |
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-04-07 | — | — | US | disclosed |
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-04-07 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| EP-2350043-B9 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-08-20 | — | — | EP | disclosed |
| EP-2350043-B1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-03-26 | — | — | EP | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| WO-2010042877-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | KDM4E 3120/4885GLA 3891/4885MEN1 3055/4885 |
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | NSUN3, SARNP, LDLR | KDM4E 3120/4885GLA 3891/4885MEN1 3055/4885 |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | KDM4E 3120/4885GLA 3891/4885MEN1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.